Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

NASDAQ:ELUT - Nasdaq - US05479K1060 - Common Stock - Currency: USD

1.99  +0.02 (+1.02%)

After market: 1.92 -0.07 (-3.52%)

Fundamental Rating

2

Taking everything into account, ELUT scores 2 out of 10 in our fundamental rating. ELUT was compared to 550 industry peers in the Biotechnology industry. ELUT may be in some trouble as it scores bad on both profitability and health. ELUT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELUT has reported negative net income.
ELUT had a negative operating cash flow in the past year.
In the past 5 years ELUT always reported negative net income.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ELUT has a worse Return On Assets (-147.29%) than 84.18% of its industry peers.
Industry RankSector Rank
ROA -147.29%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

ELUT's Gross Margin of 43.30% is fine compared to the rest of the industry. ELUT outperforms 75.27% of its industry peers.
ELUT's Gross Margin has been stable in the last couple of years.
ELUT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELUT has been increased compared to 1 year ago.
Compared to 5 years ago, ELUT has more shares outstanding
ELUT has a worse debt/assets ratio than last year.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.60, we must say that ELUT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ELUT (-9.60) is worse than 72.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.6
ROIC/WACCN/A
WACC12.5%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.81 indicates that ELUT may have some problems paying its short term obligations.
ELUT has a worse Current ratio (0.81) than 89.82% of its industry peers.
ELUT has a Quick Ratio of 0.81. This is a bad value and indicates that ELUT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.70, ELUT is not doing good in the industry: 90.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.7
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.21% over the past year.
Looking at the last year, ELUT shows a small growth in Revenue. The Revenue has grown by 4.86% in the last year.
ELUT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.69% yearly.
EPS 1Y (TTM)23.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)4.86%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-9.92%

3.2 Future

ELUT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.00% yearly.
Based on estimates for the next years, ELUT will show a very strong growth in Revenue. The Revenue will grow by 46.67% on average per year.
EPS Next Y73.57%
EPS Next 2Y35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.73%
Revenue Next 2Y46.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELUT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

ELUT's earnings are expected to grow with 35.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELUTIA INC

NASDAQ:ELUT (8/12/2025, 8:00:02 PM)

After market: 1.92 -0.07 (-3.52%)

1.99

+0.02 (+1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-14 2025-08-14/amc
Inst Owners40.95%
Inst Owner ChangeN/A
Ins Owners2.32%
Ins Owner Change4.13%
Market Cap81.83M
Analysts82.5
Price Target7.65 (284.42%)
Short Float %0.12%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.11%
Min EPS beat(2)-1.96%
Max EPS beat(2)52.18%
EPS beat(4)2
Avg EPS beat(4)-39.76%
Min EPS beat(4)-235.71%
Max EPS beat(4)52.18%
EPS beat(8)2
Avg EPS beat(8)-49.87%
EPS beat(12)4
Avg EPS beat(12)-30.92%
EPS beat(16)5
Avg EPS beat(16)-26.09%
Revenue beat(2)0
Avg Revenue beat(2)-10.12%
Min Revenue beat(2)-11.1%
Max Revenue beat(2)-9.14%
Revenue beat(4)0
Avg Revenue beat(4)-9.88%
Min Revenue beat(4)-12.03%
Max Revenue beat(4)-7.25%
Revenue beat(8)2
Avg Revenue beat(8)-5.68%
Revenue beat(12)3
Avg Revenue beat(12)-4%
Revenue beat(16)4
Avg Revenue beat(16)-3.12%
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)0%
EPS NY rev (3m)16.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.74
BVpS-0.89
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.3%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.54%
Cap/Sales 3.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.7
Altman-Z -9.6
F-Score4
WACC12.5%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y73.57%
EPS Next 2Y35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.86%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-9.92%
Revenue Next Year15.73%
Revenue Next 2Y46.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.11%
OCF growth 3YN/A
OCF growth 5YN/A